Company information - Equity financing (Details)
€ / shares in Units, $ / shares in Units, € in Thousands |
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
May 07, 2025
EUR (€)
€ / shares
shares
|
Dec. 19, 2024
EUR (€)
€ / shares
shares
|
Oct. 17, 2024
EUR (€)
€ / shares
shares
|
Jul. 18, 2024 |
Jan. 04, 2024
€ / shares
shares
|
Aug. 31, 2023
EUR (€)
€ / shares
shares
|
Nov. 30, 2025
EUR (€)
€ / shares
shares
|
Nov. 30, 2025
USD ($)
$ / shares
shares
|
Oct. 31, 2025
USD ($)
|
May 31, 2025
EUR (€)
€ / shares
shares
|
Nov. 30, 2022
shares
|
Dec. 31, 2025
EUR (€)
$ / €
€ / shares
shares
|
Dec. 31, 2024
EUR (€)
$ / €
€ / shares
shares
|
Dec. 31, 2023
EUR (€)
$ / €
|
Nov. 12, 2025
USD ($)
|
Jul. 07, 2025
$ / €
|
May 09, 2025
$ / €
|
Dec. 11, 2024
€ / shares
shares
|
Oct. 14, 2024
EUR (€)
$ / €
|
Dec. 12, 2023
$ / €
|
May 22, 2023
$ / €
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
|
|
|
|
|
|
|
|
|
|
|
€ 206,441
|
€ 57,338
|
€ 30,589
|
|
|
|
|
|
|
|
| Transaction costs related to capital increase |
|
|
|
|
|
|
|
|
|
|
|
17,134
|
9,605
|
€ 2,511
|
|
|
|
|
|
|
|
| Issue of prefunded warrants |
|
|
|
|
|
|
|
|
|
|
|
58,206
|
€ 58,234
|
|
|
|
|
|
|
|
|
| Derivative financial liabilities |
|
|
|
|
|
|
|
|
|
|
|
€ 119,385
|
|
|
|
|
|
|
|
|
|
| Exchange rate at the end of period | $ / € |
|
|
|
|
|
|
|
|
|
|
|
1.175
|
1.0389
|
1.105
|
|
|
|
|
|
|
|
| 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
|
|
|
|
|
|
€ 115,600
|
|
|
|
|
|
|
|
|
|
|
|
| Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
€ 94,100
|
|
|
|
|
|
|
|
|
| Net proceeds |
|
|
|
|
|
|
|
|
|
|
|
|
86,600
|
|
|
|
|
|
|
|
|
| Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
€ 21,400
|
|
|
|
|
|
|
|
|
|
|
21,400
|
|
|
|
|
|
|
|
|
| Net proceeds |
|
€ 20,100
|
|
|
|
|
|
|
|
|
|
|
€ 20,100
|
|
|
|
|
|
|
|
|
| Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
€ 115,600
|
|
|
|
|
|
|
|
|
115,600
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds |
€ 108,500
|
|
|
|
|
|
|
|
|
108,500
|
|
|
|
|
|
|
|
|
|
|
|
| ATM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum aggregate sales proceeds | $ |
|
|
|
|
|
|
|
|
$ 100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of dilution subject to regulatory limit |
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rolling period |
|
|
|
|
|
|
|
|
12 months
|
|
|
|
|
|
|
|
|
|
|
|
|
| August 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from issuance of equity and royalty certificates |
|
|
|
|
|
€ 35,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
|
|
|
9,618,638
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € / shares |
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price | € / shares |
|
|
|
|
|
€ 3.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
|
|
|
|
|
€ 30,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from issuing shares |
|
|
|
|
|
28,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Transaction costs related to capital increase |
|
|
|
|
|
€ 2,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of discount to volume weighted average trading price of Company's ADS |
|
|
|
|
|
0.22%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum | 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Structured Financing amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 348,000
|
|
|
| Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Structured Financing amount |
|
|
|
|
|
|
|
|
|
€ 348,000
|
|
|
|
|
|
|
|
|
€ 116,000
|
|
|
| ADS | Registered underwritten public offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum aggregate sales proceeds | $ |
|
|
|
|
|
|
|
$ 172,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
|
|
|
|
44,805,193
|
44,805,193
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of ordinary shares represented by each ADS |
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
|
|
|
|
|
|
|
$ 3.85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
|
|
|
|
|
|
€ 149,000
|
$ 172,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from issuing shares |
|
|
|
|
|
|
€ 139,400
|
$ 161,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADS | Upsized underwritten public offering including underwriters' options, at the market program |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
|
|
|
|
44,805,193
|
44,805,193
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € / shares |
|
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of ordinary shares represented by each ADS |
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | (per share) |
|
|
|
|
|
|
€ 3.33
|
$ 3.85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
|
|
|
|
|
|
€ 149,000
|
$ 172,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from issuing shares |
|
|
|
|
|
|
€ 139,400
|
$ 161,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exchange rate at the end of period | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.1576
|
|
|
|
|
|
|
| T1 New Share | Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
34,600,507
|
|
|
|
|
|
|
|
|
|
34,600,507
|
|
|
|
|
|
|
|
|
| Price per share | € / shares |
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
| T1 bis Shares | Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
7,872,064
|
|
|
|
|
|
|
|
|
|
|
7,872,064
|
|
|
|
|
|
|
|
|
| Price per share | € / shares |
|
€ 1.35
|
|
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
| T2 New Share | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
42,488,883
|
|
42,488,883
|
|
|
|
|
|
|
42,488,883
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € / shares |
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | € / shares |
€ 1.35
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
€ 57,400
|
|
€ 57,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABSAs | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price per unit | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of shares |
|
|
|
|
|
|
|
|
|
€ 57,400
|
|
|
|
|
|
|
|
|
|
|
|
| Finance contract with EIB |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
|
|
|
|
|
|
|
|
2,266,023
|
|
|
|
|
|
|
|
|
|
|
| Finance contract with EIB, second tranche (Tranche B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
|
|
3,144,654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares per warrant | shares |
|
|
|
|
1
|
|
|
|
|
|
|
5.05
|
2.13
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
€ 3.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price per warrant | € / shares |
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Royalty Certificates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of right annual royalties on future net sales for royalty certificate holders |
|
|
|
|
|
|
|
|
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
| Term of royalty certificate |
|
|
|
14 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 Royalty Certificates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of right annual royalties on future net sales for royalty certificate holders |
|
|
|
|
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
|
| T2 New Shares Call options | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative financial liabilities |
|
|
|
|
|
|
|
|
|
78,200
|
|
|
|
|
|
|
|
|
|
|
|
| T2 BSA Call options | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative financial liabilities |
|
|
|
|
|
|
|
|
|
€ 79,900
|
|
|
|
|
|
|
|
|
|
|
|
| T1 BSA Warrants | Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
94,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds |
|
|
€ 86,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
35,399,481
|
|
|
|
|
|
|
|
|
|
35,399,481
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
35,399,481
|
|
|
|
|
|
|
|
|
|
35,399,481
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
| Subscription price per warrant | € / shares |
|
|
€ 1.34
|
|
|
|
|
|
|
|
|
|
€ 1.34
|
|
|
|
|
|
|
|
|
| T1 bis BSA Warrants | Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
8,053,847
|
|
|
|
|
|
|
|
|
|
|
8,053,847
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
8,053,847
|
|
|
|
|
|
|
|
|
|
|
8,053,847
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
| Subscription price per warrant | € / shares |
|
€ 1.34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| T2 BSA Prefunded Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable term |
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| T2 BSA Prefunded Warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nominal value | € / shares |
€ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
43,437,036
|
|
|
|
|
|
|
|
|
43,437,036
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares per warrant | shares |
1
|
|
|
|
|
|
|
|
|
1
|
|
|
1
|
|
|
|
|
1
|
|
|
|
| Issue of prefunded warrants |
€ 58,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
|
|
|
43,437,036
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price per warrant | € / shares |
€ 1.34
|
|
|
|
|
|
|
|
|
€ 1.34
|
|
|
|
|
|
|
|
|
|
|
|
| T2 BSA Prefunded Warrants | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
| T3 BSA warrants | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional proceeds receivable upon exercise of warrants |
€ 116,000
|
|
|
|
|
|
|
|
|
|
|
€ 116,000
|
|
|
|
|
|
|
|
|
|
| T3 BSAs Warrants Attached To T2 New Shares | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants in each unit | shares |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
|
|
|
38,239,990
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.5
|
|
|
|
|
|
|
|
|
|
|
|
| T3 BSAs Warrants Attached To T2 New Shares | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional proceeds receivable upon exercise of warrants |
|
|
|
|
|
|
|
|
|
€ 57,400
|
|
|
|
|
|
|
|
|
|
|
|
| T3 BSAs Warrants Attached To T2 BSA Warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants in each unit | shares |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
|
|
|
39,093,329
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.5
|
|
|
|
|
|
|
|
|
|
|
|
| T3 BSAs Warrants Attached To T2 BSA Warrants | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional proceeds receivable upon exercise of warrants |
|
|
|
|
|
|
|
|
|
€ 58,600
|
|
|
|
|
|
|
|
|
|
|
|
| ABSA warrants | T2 New Share | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
| T2 and T3 BSAs | Maximum | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
|
|
|
120,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| PFW-BSAs | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subscription price per unit | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.34
|
|
|
|
|
|
|
|
|
|
|
|
| Issue of prefunded warrants |
|
|
|
|
|
|
|
|
|
€ 58,200
|
|
|
|
|
|
|
|
|
|
|
|
| Lanifibranor | 2023 Royalty Certificates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of right annual royalties on future net sales for royalty certificate holders |
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum royalties payable to royalty certificate holders |
|
|
|
|
|
€ 92,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term of royalty certificate |
|
|
|
|
|
15 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Royalty Certificates | Lanifibranor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of right annual royalties on future net sales for royalty certificate holders |
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Licensing and collaboration agreement with CTTQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exchange rate at the end of period | $ / € |
|
|
|
|
|
|
|
|
|
|
|
1.175
|
|
|
|
1.1755
|
1.125
|
|
1.092
|
1.08
|
1.082
|